Literature DB >> 10621853

bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study.

A Piattelli1, M Fioroni, A Santinelli, C Rubini.   

Abstract

In a double-blind study 10 patients with oral leukoplakia were treated daily (three topical applications) with 0.1% isotretinoin gel or a placebo for 4 months. Nine patients completed the treatment, while one patient was lost to follow-up. Subsequently, the patients who had received the placebo used the active medication for an additional 4 months. All patients treated with the active medication showed a significant improvement of the oral lesions while, in the patients receiving only the placebo, the size of the lesions remained the same. Also the group of patients who received the active medication after the placebo showed an improvement in the size and clinical appearance of the lesions. A complete response was defined as the complete disappearance of the lesion as assessed by visual inspection, while a partial response was defined as a 50% or more reduction in the size of the lesions. In total we had a complete response and eight partial responses. No side-effects from the use of the gel were ever observed. The percentage of bcl-2-positive cells was evaluated in the basal layer from a minimum of 1000 cells in each case and the bcl-2 immunostaining was scored using three groups: - (< or = 10% cells); + (< or = 50% cells); +2 (> or = 50% cells). The presence of apoptotic bodies was evaluated in a random fashion in the parabasal layer in 20 HPF. Immunohistochemical analysis for bcl-2 protein showed that before treatment a weak positivity of the basal layers, with a focal positivity of some parabasal cells, was present: five out of nine specimens were positive. Only a few apoptotic bodies were observed. After treatment in almost all specimens it was possible to observe a complete bcl-2 negativity with a positivity in only one specimen out of nine. An increase in apoptotic bodies was observed. Statistical analysis showed that the difference between the bcl-2 positivity in the two groups was not statistically significant (P = 0.134) while, on the contrary, the difference in the count of the apoptotic bodies between the same two groups was statistically significant (P = 0.0193). In conclusion, the data obtained from this pilot study show that good results can be obtained with the topical use of 13-cis-retinoic acid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621853     DOI: 10.1016/s1368-8375(98)00095-5

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  7 in total

1.  Use of oral isotretinoin in the management of rosacea.

Authors:  Hyunhee Park; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

Review 2.  Should local drug delivery systems be used in dentistry?

Authors:  Joana Vieira Costa; Jaime Portugal; Cristina Bettencourt Neves; Ana F Bettencourt
Journal:  Drug Deliv Transl Res       Date:  2021-09-20       Impact factor: 4.617

3.  A review of the nonsurgical treatment of oral leukoplakia.

Authors:  Adriana Spinola Ribeiro; Patrícia Ribeiro Salles; Tarcília Aparecida da Silva; Ricardo Alves Mesquita
Journal:  Int J Dent       Date:  2010-02-23

4.  Interplay between EGR1 and SP1 is critical for 13-cis retinoic acid-mediated transcriptional repression of angiotensin type 1A receptor.

Authors:  Russell Snyder; Thomas Thekkumkara
Journal:  J Mol Endocrinol       Date:  2013-04-23       Impact factor: 5.098

5.  Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.

Authors:  Andrew S Holpuch; Kashappa-Goud H Desai; Steven P Schwendeman; Susan R Mallery
Journal:  J Carcinog       Date:  2011-09-21

6.  Estimation of oral leukoplakia treatment records in the research of the Department of Maxillofacial and Oral Surgery, Medical University of Gdansk.

Authors:  Anna Starzyńska; Anita Pawłowska; Dorota Renkielska; Igor Michajłowski; Michał Sobjanek; Izabela Błażewicz; Adam Włodarkiewicz
Journal:  Postepy Dermatol Alergol       Date:  2015-03-30       Impact factor: 1.837

7.  EVALUATION OF INNOVATIVE DIGITALLY CONTROLLED ER:YAG LASER IN SURGICAL TREATMENT OF ORAL LEUKOPLAKIA - A PRELIMINARY STUDY.

Authors:  Dragana Gabrić; Vlaho Brailo; Aleksandra Ivek; Karla Krpan; Nena Matulić; Danko Velimir Vrdoljak; Anja Baraba; Vanja Vučićević Boras
Journal:  Acta Clin Croat       Date:  2019-12       Impact factor: 0.780

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.